16 results about "Insulin tolerance" patented technology

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or derivatives thereof or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating polycystic ovarian syndrome (PCOS). The beta-elemonic acid is screened from a medicinal and edible library, and experiments prove that the beta-elemonic acid can remarkably improve the PCOS ovarian form and the number of mature follicles, normalize the disordered estrus cycle, remarkably improve the serum hormone level and further remarkably improve the sugar tolerance, insulin tolerance and weight of PCOS. The beta-elemonic acid disclosed by the invention is a compound based on homology of medicine and food, can be used as a medicine as well as a natural ingredient of food, is relatively low in toxicity, ensures the safety after long-term use, is relatively low in safety evaluation cost of a relatively brand-new synthetic compound, and can be applied to development and preparation of a medicine or a lead compound thereof for preventing and / or treating PCOS, or a health care product.

The invention belongs to the technical field of biology, and particularly relates to animal bifidobacterium subsp. Lactis FMBL B24304AHDM and application thereof.The animal bifidobacterium subsp. Lactis FMBL B24304AHDM is preserved in the China Center for Type Culture Collection on November 18, 2024, the preservation number is CCTCC NO: M 20242505, and the animal bifidobacterium subsp. Lactis FMBL B24304AHDM has the good inhibition capacity on pathogenic bacteria and has the high scavenging capacity on DPPH and ABTS free radicals; the compound has the effect of inhibiting the activity of alpha-glucosidase, alpha-amylase and dipeptidyl peptidase IV, and the oral glucose tolerance and insulin tolerance of T2DM mice can be remarkably reduced; the composition of intestinal microbiome is obviously improved, the abundance and variety of effective microbial communities in the intestinal tract are improved, and the relative abundance of pathogenic bacteria is reduced, so that the disorder of short-chain fatty acids of T2DM mice is improved, and the application prospect is wide.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The invention relates to the technical field of biology, in particular to a probiotic composition for reducing blood sugar and application thereof.The probiotic composition comprises bifidobacterium longum subsp. Longum FMBL B241770LS and bifidobacterium animalis subsp. Lactis FMBL B24304AHDM which are preserved in the China Center for Type Culture Collection on September 21, 2024 with the preservation number of CCTCC NO: M 20241993 and preserved in the China Center for Type Culture Collection on November 18, 2024 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the the preservation number is CTCC (China Type Culture Collection) NO: M 20242505; the compound has a good inhibition effect on pathogenic bacteria, can obviously reduce oral glucose tolerance and insulin tolerance of T2DM mice, reduce abnormal fluctuation of postprandial blood glucose, reduce fasting blood glucose, fasting insulin level and blood fat level, relieve insulin resistance, effectively regulate intestinal flora imbalance and promote generation of short-chain fatty acid in intestinal tracts of the T2DM mice.

The compositions and methods for improving or regulating GLP-1 levels, stimulating GLP-1 secretion, ameliorating metabolism including losing weight, managing glucose or insulin tolerance including stimulating insulin secretion, inhibiting glucagon secretion and reducing fasting glucose levels. The compositions comprise β-aminoisobutyric acid, a physiologically acceptable salt, polymer, ester, or 3-hydroxy-3-methylbutanoic acid, a physiologically acceptable salt, polymer, ester, or tributyrin or tributyrin derivative, or mixture thereof.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

The invention relates to the technical field of diabetes medicine development, in particular to a three-target-point active peptide, a fusion protein and application of the three-target-point active peptide and the fusion protein. The invention provides an active peptide and a fusion protein with GLP-1 / GIP / GCG three targets, and test results show that the active peptide and the fusion protein both have GLP-1 / GIP / GCG three-target activity, can significantly improve glucose tolerance and insulin tolerance, can significantly reduce the proportion of glycosylated hemoglobin, and can significantly improve the activity of the GLP-1 / GIP / GCG three targets. Wide application prospects are realized in the fields of blood glucose control and / or metabolic disease prevention and treatment.

The application discloses a method for relieving obesity cardiomyopathy lipid toxicity by Chemerin and belongs to the technical field of pharmacological research. Mice are selected to establish an obesity mouse model, and are equally divided into a control group, a high-fat diet group, an AAV CMKLR1 virus group, and a high-fat + AAV CMKLR1 virus group. In succession, mouse heart ultrasound, TSE system detection, glucose tolerance test, and insulin tolerance test are carried out, and mouse blood glucose is measured at intervals. Then, tissue protein is extracted for protein immunoblotting, and tissue RNA is extracted for reverse transcription, and then qPCR is used to detect the expression of related genes. After paraffin embedding and slicing of mouse tissues, HE, WGA, immunofluorescence and other pathological staining are carried out. MTBE method is used for lipid extraction and detection of lipid content. ELISA method is used to measure serum Chemerin, and Acyl-RAC method is used to detect protein palmitoylation. Finally, the experimental results are analyzed to draw a conclusion. The present application proves by clinical data and mouse models that Chemerin compensatorily increases in the process of obesity, and Chemerin can relieve cardiac lipid toxicity caused by obesity and protect cardiac function.

The application belongs to the technical field of medicine preparation, and particularly relates to application of cellulose nanofiber in preparation of medicine for preventing or treating gestational diabetes mellitus. In the application, the CNF has significant adsorption capacity for micro / nano plastic due to its high specific surface area and unique surface characteristics. Moreover, the CNF intervention can effectively reduce the deposition of microplastics in organs such as liver and placenta, and reduce the trans-barrier transport and biological toxicity of harmful particles from the source. In addition, the CNF can effectively repair the intestinal barrier damage caused by microplastic exposure or high-fat diet, and reduce the systemic inflammation level. Furthermore, the CNF intervention can significantly reduce the fasting blood glucose of the microplastic exposure model mouse during pregnancy, improve the area under the curve (AUC) of insulin tolerance test (ITT) and oral glucose tolerance test (OGTT), and restore the insulin sensitivity.

The invention discloses an application of GPR110 as a therapeutic target of type 2 diabetes mellitus. The application discovers that the GPR110 gene is used as a therapeutic target of type 2 diabetes for the first time, and provides application of adenovirus-mediated GPR110 gene overexpression in preparation of drugs for treating type 2 diabetes. In an adult type 2 diabetes mouse model db / db, through caudal vein injection of adenovirus-mediated GPR110 overexpression, it is found that the type 2 diabetes related symptoms are significantly improved. The blood glucose level and the fasting blood glucose level are obviously reduced, and an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved. In addition, a decrease in serum insulin level prompts a reduction in pancreatic islet function burden. The results show that the adenovirus-mediated GPR110 overexpression can effectively improve the metabolic disorder of mice with type 2 diabetes mellitus, and a new intervention method and means are provided for the treatment of the type 2 diabetes mellitus.

The invention discloses a composition for diabetes. The composition comprises carbohydrate, dietary fiber, protein, grease and trace elements. The composition can reduce fasting blood glucose levels, reduce serum triglyceride and total cholesterol levels, increase high density lipoprotein levels and improve insulin tolerance in diabetic patients. Therefore, the composition is used for preparing medicines or health-care products for treating and / or preventing diabetes mellitus.

Therapeutic approaches are provided for the immunomodulatory control of metabolic dysregulation, including the treatment of subjects suffering from a metabolic dysregulation or a complication thereof, or for improving glucose and / or insulin tolerance and / or weight control in a subject, involving the administration of repeated doses of an immunogenic composition comprising whole killed or attenuated cells of an endogenous bacterial pathogen.

Disclosed is an application of glycerol monodecanoate (GMD) in the preparation of a hypoglycemic drug or a functional food, falling within the technical field of medicine. According to the present disclosure, the hypoglycemic and insulin resistance-improving functions of GMD are first revealed. Studies demonstrate that GMD can enhance glucagon-like peptide-1 (GLP-1) secretion, activate hepatic glycolysis and insulin receptor (INSR)-related gene expression, while inhibiting hepatic gluconeogenesis pathway-related gene expression. Notably in type 2 diabetes mellitus (T2DM), glucose-lowering efficacy of GMD is comparable to metformin, and it outperforms metformin in regulating glucose tolerance and insulin tolerance, with significant alleviation of polydipsia. Moreover, as GMD is a naturally occurring edible substance with a high safety profile, it has a good application prospect in the preparation of a drug for treating hyperglycemia and diabetes, or a functional food to assist in lowering blood glucose.

The application belongs to the technical field of biological medicine, and discloses application of beta-elemene acid or a derivative or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating polycystic ovary syndrome (PCOS). The beta-elemene acid is screened from a medicinal and edible homology library, and experiments prove that the beta-elemene acid can significantly improve the ovary morphology and mature follicle quantity of PCOS, normalize the estrous cycle, significantly improve the serum hormone level, and also significantly improve the glucose tolerance, insulin tolerance and body weight of PCOS. The beta-elemene acid of the application is a compound based on medicinal and edible homology, which can be used as a medicine and also as a natural ingredient of food, has low toxicity, is safe in long-term use, has low cost of safety evaluation of a relatively new synthetic compound, and can be applied to development and preparation of a medicine for preventing and / or treating PCOS or a lead compound thereof.

The application discloses application of N-acetylserotonin in preparation of a medicine for treating type 2 diabetes, and belongs to the field of biological medicines. The application proves through in-vivo and in-vitro experiments that N-acetylserotonin can promote the secretion of GLP-1, has obvious effects of lowering blood sugar, good glucose tolerance and good insulin tolerance, and has obvious improvement on high fasting blood sugar, high postprandial blood sugar, poor glucose tolerance and decreased insulin tolerance. The application has obvious improvement on insufficient GLP-1 secretion. The application has important significance for maintaining stable blood sugar and improving glucose and insulin tolerance of diabetes patients, and provides a new solution for type 2 diabetes treatment.

The invention discloses application of ketoisophorone and benzyl benzoate in preparation of a medicine for treating diabetes, and belongs to the technical field of biological medicine. In-vivo and in-vitro studies find that after a T2DM animal model and a GlcN cell model are treated through KSP independent administration, BZT independent administration and KSP and BZT 1: 3 combined administration, compared with a model group, the blood glucose regulation effect of a combined administration group is most remarkable: the area under an fasting blood glucose and oral glucose tolerance test (OGTT) curve is in dose-dependent reduction, and the area under the curve is in dose-dependent reduction; an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved; in animal experiments, glycogen generation in liver tissues is increased, and balloon-like deformation and fatty degeneration accumulation conditions are relieved.